Peripheral blood stem cell support allows dose intensification of multiple cycle chemotherapy for metastatic tumors, including pediatric sarcomas. The VACIME protocol (vincristine, adriamycin, cyclophosphamide, ifosfamide, mesna and etoposide) utilizes peripheral blood stem cells (PBSC) collected following the treatment cycle as support for subsequent dose-and timeintensive chemotherapy. A critical assumption is that PBSC collected in this manner will be purged of residual tumor cells in vivo. We tested this assumption using sensitive reverse-transcriptase polymerase chain reaction (RT-PCR) to assess the presence of the characteristic translocations of the Ewing's sarcoma family of tumors (ESFT) and alveolar rhabdomyosarcoma (ARMS), t(11;22), and t(2;13), respectively. We used RT-PCR to evaluate 122 samples of peripheral blood (PB), bone marrow (BM) and PBSC collected from 12 pediatric patients with metastatic ESFT and ARMS. The samples included pre-therapy BM and PB, as well as BM, PB, and PBSC collections at various times in the VACIME treatment course. Molecular evidence of tumor contamination was detected in 1/40 PBSC collections from 12 patients. In all patients, we documented clearance of disease by RT-PCR in peripheral blood and bone marrow by week 9 of the VACIME protocol. In vivo purging in combination with the intensive VAC-IME regime appears to be effective in removing tumor cells from PBSC, bone marrow, and peripheral blood as detected by RT-PCR.
therapy, surgery and radiation therapy aim to improve survival by the use of dose-and time-intensive therapy. Peripheral blood stem cell (PBSC) support can ameliorate the hematopoietic toxicity of intensive chemotherapy and allow maximal dose intensification. [3] [4] [5] PBSC can be mobilized with granulocyte colony-stimulating factor (G-CSF) following multi-agent chemotherapy and reinfused as a stem-cell rescue following severely myelosuppressive therapy. However, since metastic sarcomas often have marrow involvement, tumor contamination in PBSC collections may contribute to relapse. Evidence of tumor contamination in PBSC collections has been documented in breast cancer, multiple myeloma, neuroblastoma, and lymphoma. [6] [7] [8] [9] Reinfused tumor cells are potentially clonogenic and therefore may contribute to relapse. 6, 7 Contamination of the bone marrow and/or PBSC product can potentially be minimized by three strategies: ex vivo purging by disease-specific antibody and complement cocktails; CD34 positive selection; or in vivo purging of residual tumor by high-dose chemotherapy. [10] [11] [12] [13] The efficiency of in vivo purging of residual disease can be tested with the polymerase chain reaction (PCR). PCR can specifically amplify a target gene sequence at a potential sensitivity of one tumor cell in a background 10 5 -10 6 normal cells. ESFT and ARMS have disease-specific genetic lesions and thus lend themselves well to PCRbased detection. Up to 95% of ESFTs have either t(11;22)(q24;q12) or t(21;22)(q22;q12), which produces either the EWS-FLI1 or EWS-ERG gene fusion product. 14, 15 Furthermore, 85% of ARMSs have either the t(2;13)(q35;q14) or t(1;13)(p36;q14) which involve translocation of the PAX3 or PAX7 to the FKHR gene. [16] [17] [18] Using RT-PCR, ESFT cells have been detected in peripheral blood, bone marrow and PBSC. [19] [20] [21] [22] ARMS cells have been detected in bone marrow. 16 We have utilized an RT-PCR amplification to serially examine 122 samples of bone marrow, PBSC and peripheral blood from nine patients with metastatic ESFT and three patients with metastatic ARMS undergoing dose intensive chemotherapy with sequential stem cell infusions. We evaluated the frequency of molecular detection of residual tumor in metastatic sarcomas at diagnosis and determined the efficiency of an in vivo purging method to eliminate minimal residual disease (MRD) in PBSC products.
Materials and methods

Patient characteristics
Patient characteristics appear in Table 1 . All patients studied were less than 19 years of age with metastatic ESFT or ARMS, histologically classified by conventional pathology with immunocytochemistry of the initial biopsy. The chromosomal fusion types listed in Table 2 were confirmed in the primary tumor samples by conventional cytogenetics or RT-PCR at the treating institution if possible. Metastatic disease was defined by radiographic examination and bilateral bone marrow biopsies and aspirates. The patients were all treated according to the VACIME protocol ( Figure 1 ). The VACIME protocol utilizes dose-and time-intensive chemotherapy with G-CSF support. To further ameliorate the myelosuppressive complications of this protocol, PBSC were collected following course 2 with reinfusion following courses 3 and 4 and again collected following course 4 with reinfusion following courses 5 and 6. All samples were obtained following informed consent from each patient (or patient's guardian). Samples were identified with unique patient numbers to assure confidentiality. The samples were collected from peripheral blood, bone marrow and peripheral blood stem cell product at the treating institution, shipped by overnight delivery on wet ice and mononuclear cells were extracted within 24-36 h of sample collection.
RT-PCR
Mononuclear cells were extracted via a salt-lysis technique. This was followed by RNA extraction using Trizol reagent (Life Technologies, Gaithersburg, MD, USA) RNA was quantified and stored at −70°C. To reduce PCR contamination, WBC isolation and RNA extraction were performed in physically separate locations. PCR preparation was also physically separate from all amplified PCR products. One microgram of RNA was transcribed to cDNA using translocation-specific primers (EWS B or RBD B) in a separate RT reaction. PCR primers are listed in Figure 
Results
Sensitivity
The nested PCR for the ESFT translocation, t (11:22) detected one tumor cell from the cell line TC-71, serially diluted in a background of 10 5 normal bone marrow cells (Figure 3a) . The nested RT-PCR for the t(2;13) translocation found in ARMS could detect one rhabdomyosarcoma cell from the cell line rh-30 in a background of 10 5 -10 6 normal bone marrow cells (Figure 3b ). For all positive assays the PCR product was confirmed by direct nucleotide sequencing to verify its identify (data not shown).
Detection of MRD
RT-PCR analysis of the specific translocations of ESFT and ARMS were perfomed on 122 peripheral blood, bone marrow and PBSC samples. The specimens were collected as the 12 patients progressed through the VACIME protocol. All 122 samples had intact RNA (confirmed with the beta-2 microglobin RT-PCR) and were analyzed by RT-PCR for evidence of the fusion product of either ESFT or ARMS.
Six patients had marrow disease detected by conventional pathology at diagnosis. RT-PCR confirmed the presence of the disease-specific fusion product in RNA correlating to their diagnosis in five of six patients. The one patient (patient no. 3), where RT-PCR failed to confirm pathology results, had insufficient intact RNA documented by the failure of beta-2 microglobulin amplification. Samples of PB, BM and PBSC were obtained from these six patients during VACIME therapy and evaluated for the presence of MRD. Two patients had further evidence of MRD detected by RT-PCR. In patient no. 1, the first PBSC collection had tumor contamination detected which subsequently cleared in later PB, BM, and PBSC samples after two additional cycles of therapy (Figures 4 and 6 ). Patient no. 11 had evidence of tumor contamination in the bone marrow sample obtained following course 2 of chemotherapy, which also subsequently cleared at the end of chemotherapy (Figures 5  and 6 ). The RT-PCR assay detected these two cases of tumor contamination where conventional methods indicated that the patient was free of metastatic disease in the BM and PB. The remaining four patients, with marrow disease at diagnosis by light microscopy, had no evidence of tumor contamination by week 9. Among the six patients with marrow disease at diagnosis, 19 PBSC samples were evaluated. Eighteen had no fusion product detected (Table 2) .
Six patients had no evidence of marrow involvement at diagnosis by standard pathological evaluation. Patient no. 2 initially was free of disease by morphology, and RT-PCR, but disease was detected in the peripheral blood by RT-PCR at week 3 of therapy. This disease was not detected by RT-PCR in subsequent samples. The remaining samples from the five other patients with no marrow disease at diagnosis by conventional pathology had no tumor contamination in any of the 35 PB, seven BM and 21 PBSC collections assayed by RT-PCR (Table 2) .
Discussion
The VACIME protocol utilizes dose-and time-intensive chemotherapy, in combination with radiation therapy and surgery in the treatment of newly diagnosed pediatric metastatic sarcoma patients. The myelosuppression induced by VACIME is ameliorated by sequential collec- tion and reinfusion of stem cells. 24, 25 In addition, the schedule of chemotherapy and PBSC collection and reinfusion (Figure 1 ) permits in vivo purging of the PBSC product of any residual malignancy. The efficacy of purging methods is difficult to assess by conventional methods, as the disease burden is often below the sensitivity of routine detection. To overcome this obstacle, we performed RT-PCR of disease-specific translocations to evaluate 122 samples collected from 12 children with either ESFT or ARMS to assess the efficiency of an in vivo purging protocol. We found evidence of metastatic disease in five of six patients with marrow disease at diagnosis and one of six with no marrow disease at diagnosis. RT-PCR revealed that in vivo purging apparently occurred in 39/40 samples from the 12 patients analyzed. The VACIME rapidly cleared (by week 9) any RT-PCR detectable disease in peripheral blood, bone marrow or PBSC. The long-term follow-up of these patients is incomplete, and it is unknown if the effective in vivo purging will translate to improved outcome.
Similar attempts to purge in vivo have been utilized in various malignancies. Saarinen et al 26 concluded that 'purging efficacy' in pediatric neuroblastoma, assayed by immunofluorescence, was a strong prognostic factor. All of the patients who had rapid clearance (within 2 months) of tumor contamination from serial PBSC collections, became disease-free survivors. This outcome compared favorably with a 67% disease-free survival in patients with slow clearance (within 6 months). All of patients who never cleared their PBSC died. 26 Previous studies have detected the disease-specific cytogenetic translocations of ESFT and ARMS. In patients at initial diagnosis, West et al 19 found circulating tumor cells in the peripheral blood or bone marrow of 25% of nonmetastatic and 50% of metastatic/relapsed ESFT patients via a RT-PCR assay. Using similar RT-PCR conditions, we found among ESFT patients 16% of patients with extramedullary disease and 33% of patients with marrow disease to have circulating tumor cells in peripheral blood samples. Such variation in tumor detection is unlikely to be secondary to technical differences in the RT-PCR, as the primer design and overall sensitivity of our assay are identical to those of West et al. Among the ARMS patients, 67% of patients with marrow disease by conventional pathology had disease detected in their peripheral blood. Our data contradicts a small study of five patients reported by Toretsky et al. 20 In their evaluation of five newly diagnosed ESFT patients, 54% of PBSC, 47% of peripheral blood and 50% of bone marrow samples had presence of the t (11;22) translocation product detectable by RT-PCR. These patient 532 samples were collected at diagnosis, during and following therapy. This discordance with our results may be secondary to differences in the chemotherapy regime, PCR techniques or patient selection. We have applied a highly sensitive RT-PCR assay to assess the efficacy of a new protocol and found rapid clearance of minimal residual disease in peripheral blood, bone marrow and PBSC with the VACIME protocol. In the future, similar approaches may allow for the rapid assessment of chemo-sensitivity, the purity of a PBSC collection, and the early detection of residual disease prior to relapse.
